Analysts Set Immunocore Holdings plc (NASDAQ:IMCR) Target Price at $80.40

Immunocore Holdings plc (NASDAQ:IMCR) has been assigned an average recommendation of “Moderate Buy” from the twelve ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $80.40.

A number of brokerages have recently issued reports on IMCR. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a research report on Monday, September 9th. JPMorgan Chase & Co. decreased their price objective on Immunocore from $70.00 to $66.00 and set an “overweight” rating on the stock in a report on Wednesday, July 10th. Barclays decreased their price objective on Immunocore from $92.00 to $66.00 and set an “overweight” rating on the stock in a report on Friday, August 9th. Oppenheimer reissued an “outperform” rating and set a $89.00 price objective (up from $87.00) on shares of Immunocore in a report on Friday, August 9th. Finally, HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Immunocore in a report on Tuesday, September 17th.

Hedge Funds Weigh In On Immunocore

A number of large investors have recently bought and sold shares of IMCR. DNB Asset Management AS increased its stake in shares of Immunocore by 35.0% during the second quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock valued at $244,000 after buying an additional 1,868 shares during the period. NEOS Investment Management LLC purchased a new position in shares of Immunocore during the fourth quarter valued at approximately $262,000. XTX Topco Ltd purchased a new position in shares of Immunocore during the second quarter valued at approximately $303,000. Tidal Investments LLC purchased a new position in shares of Immunocore during the first quarter valued at approximately $423,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Immunocore by 69.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 6,621 shares of the company’s stock valued at $430,000 after buying an additional 2,721 shares during the period. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Stock Performance

Shares of IMCR opened at $30.50 on Friday. The company has a market cap of $1.53 billion, a PE ratio of -25.00 and a beta of 0.72. The company has a current ratio of 5.17, a quick ratio of 5.15 and a debt-to-equity ratio of 1.31. The stock has a 50-day moving average price of $35.25 and a 200-day moving average price of $44.55. Immunocore has a 12-month low of $29.72 and a 12-month high of $76.98.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.25. The firm had revenue of $75.40 million during the quarter, compared to the consensus estimate of $74.58 million. Immunocore had a negative return on equity of 14.68% and a negative net margin of 19.16%. The company’s revenue for the quarter was up 26.2% on a year-over-year basis. During the same quarter last year, the company posted ($0.37) EPS. As a group, equities analysts forecast that Immunocore will post -1.79 earnings per share for the current fiscal year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.